Biologic Dosimetry of 188Re-HDD/Lipiodol Versus 131I-Lipiodol Therapy in Patients with Hepatocellular Carcinoma
Kim De Ruyck, MSc1,
Bieke Lambert, MD2,
Klaus Bacher, MSc1,
Filip Gemmel, MD2,
Filip De Vos, PhD2,
Anne Vral, PhD1,
Leo de Ridder, MD, PhD1,
Rudi A. Dierckx, MD, PhD2 and
Hubert Thierens, PhD1
1 Department of Anatomy, Embryology, Histology, and Medical Physics, Ghent University, Gent, Belgium
2 Division of Nuclear Medicine, Ghent University Hospital, Gent, Belgium
View larger version (107K):
[in a new window]
|
FIGURE 1. Total-body scans for 131I-lipiodol (A) and 188Re-HDD/lipiodol (B) for the same patient. These scans were obtained 14 d and 54 h, respectively, after administration of the activity.
|
|
View larger version (16K):
[in a new window]
|
FIGURE 2. Yield of DCs in lymphocytes of HCC patients after in vitro irradiation, vs. the standard dose-response curve for a healthy population.
|
|
View larger version (13K):
[in a new window]
|
FIGURE 3. Distribution of radiation-induced DCs after 2 Gy of in vitro irradiation in healthy donors and HCC patients. The vertical line represents the cutoff between radiosensitive and nonradiosensitive individuals based on the 90th percentile of the control population.
|
|
View larger version (20K):
[in a new window]
|
FIGURE 4. Time plot of DC yield in patients undergoing multiple subsequent therapies with 131I-lipiodol (A) or 188Re-HDD/lipiodol (B).
|
|
View larger version (15K):
[in a new window]
|
FIGURE 5. Comparison of the ETBD between 131I-lipiodol and 188Re-HDD/lipiodol at 1 and 2 wk after administration for 131I-lipiodol and at 1 and 2 d after administration for 188Re-HDD/lipiodol. Error bars represent the SD on the mean (SDM).
|
|
View larger version (26K):
[in a new window]
|
FIGURE 6. Plot of the WBC (A) and thrombocyte (B) counts vs. time after 188Re-HDD/lipiodol administration.
|
|
Copyright © 2004 by the Society of Nuclear Medicine.
